Charles River Laboratories International Inc
NYSE:CRL

Watchlist Manager
Charles River Laboratories International Inc Logo
Charles River Laboratories International Inc
NYSE:CRL
Watchlist
Price: 195.77 USD 0.81% Market Closed
Market Cap: 10B USD
Have any thoughts about
Charles River Laboratories International Inc?
Write Note

Charles River Laboratories International Inc
Pre-Tax Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Charles River Laboratories International Inc
Pre-Tax Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Pre-Tax Income CAGR 3Y CAGR 5Y CAGR 10Y
Charles River Laboratories International Inc
NYSE:CRL
Pre-Tax Income
$518.6m
CAGR 3-Years
2%
CAGR 5-Years
14%
CAGR 10-Years
12%
Thermo Fisher Scientific Inc
NYSE:TMO
Pre-Tax Income
$6.8B
CAGR 3-Years
-12%
CAGR 5-Years
11%
CAGR 10-Years
13%
Danaher Corp
NYSE:DHR
Pre-Tax Income
$4.1B
CAGR 3-Years
-17%
CAGR 5-Years
7%
CAGR 10-Years
2%
Mettler-Toledo International Inc
NYSE:MTD
Pre-Tax Income
$955.2m
CAGR 3-Years
1%
CAGR 5-Years
7%
CAGR 10-Years
8%
Agilent Technologies Inc
NYSE:A
Pre-Tax Income
$1.5B
CAGR 3-Years
9%
CAGR 5-Years
11%
CAGR 10-Years
N/A
IQVIA Holdings Inc
NYSE:IQV
Pre-Tax Income
$1.5B
CAGR 3-Years
17%
CAGR 5-Years
33%
CAGR 10-Years
12%
No Stocks Found

Charles River Laboratories International Inc
Glance View

Market Cap
10B USD
Industry
Life Sciences Tools & Services

Charles River Laboratories International Inc. is a leading provider of essential research services and products that support the global clinical development of new drugs. Founded in 1947, the company has evolved from a small laboratory in Massachusetts to a formidable player within the biotech and pharmaceutical sectors. Its comprehensive suite of offerings includes preclinical and clinical laboratory services, along with a range of research models that help organizations like pharmaceutical companies and academic institutions navigate the complexities of drug development. By partnering with clients from early-stage discovery through to advanced trials, Charles River plays a pivotal role in bringing innovative therapies to market while maintaining a strong commitment to animal welfare and ethical research practices. As an investment opportunity, Charles River Laboratories stands out due to its solid financial performance, buoyed by a strategic focus on expanding its capabilities and services. The company has shown robust revenue growth over the years, driven by increasing demand for outsourced laboratory services, especially as the biotech landscape becomes more competitive. With a dedicated management team and a continual investment in technology and infrastructure, Charles River is well-positioned to capitalize on the rising need for more efficient drug development processes. Investors can take confidence from the company's strong market presence, consistent execution, and strategic acquisitions that enhance its service offerings, making it a compelling choice for those looking to invest in the healthcare space.

CRL Intrinsic Value
227.11 USD
Undervaluation 14%
Intrinsic Value
Price

See Also

What is Charles River Laboratories International Inc's Pre-Tax Income?
Pre-Tax Income
518.6m USD

Based on the financial report for Sep 28, 2024, Charles River Laboratories International Inc's Pre-Tax Income amounts to 518.6m USD.

What is Charles River Laboratories International Inc's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 10Y
12%

Over the last year, the Pre-Tax Income growth was -16%. The average annual Pre-Tax Income growth rates for Charles River Laboratories International Inc have been 2% over the past three years , 14% over the past five years , and 12% over the past ten years .

Back to Top